As per a recent announcement by a specialty pharmaceutical company, the FDA has approved its tramadol hydrochloride Oral Solution 5mg/1mL C-IV for the management of severe pain management enough to require an opioid analgesic and for which substitute therapies are ineffective in adults on 1 September, 2020.

A substantial amount of patients suffers from high-impact chronic pain that hinders with routine life or work activities. In May, 2019, WHO the U.S. Department of Health and Human Services accentuated the necessity for an "personalized, patient-centered" method for pain treatment.

This newly FDA-approved opioid agonist in oral liquid formulation allows the physicians flexibility to titrate dosing exactly as per distinct patients' needs," said the President and CEO of this company. Furthermore, for patients with dysphagia (swallowing dysfunction) or who merely have issues regarding swallowing pills, this tramadol oral solution offers an edge over different tramadol forms. Tramadol hydrochloride oral solution has a patent awaiting.